Manhattan Research's Webinar - Physician Digital Resource and Communication Mix for Brand Success

Manhattan ResearchMark Bard, president of pharmaceutical and healthcare market research company Manhattan Research, will host a complimentary physician marketing webinar on Tuesday, August 4 at 11am and 3pm EDT. The webinar, ePharma Physician® v9.0: Navigating the Physician Digital Resource Mix, will preview the data and insights available in the company's recently released ePharma Physician® study and advisory service.

ePharma Physician® differentiates itself from Manhattan Research's broader physician studies by probing deeper into the digital resource and communication preferences of physicians interacting with pharmaceutical, device, and biotech companies online. This group of "ePharma Physicians" has now reached a significant 87% of the total U.S. physician population, making it necessary for manufacturers, agencies, and medical content providers to understand this market and leverage technology in building successful relationships.

"As digital becomes a core part of the brand planning discussion, marketers and our agency clients are demanding deeper insight into the specific sites physicians are using online - and they want to know what these visitors think of their site as well as the competition," said Mr. Bard. "In addition to tracking online journals, specialty sites, corporate sites, and product sites by specialty, we combine that research with a review of 'what if' scenarios to help our clients better understand what physicians want from the next generation of the clinical web."

During the August 4th webinar, Mr. Bard will review the following key questions:

  • In what ways is the shifting professional resource and communication mix affecting physician interaction with pharmaceutical and device companies?
  • How can marketers leverage their specific physician audience's journal, specialty, product and corporate site mix to dictate more intelligent media plans in 2010?
  • Is email a viable communication channel in the manufacturer-physician relationship?
  • How are companies using interactive detailing, video conferencing, and portals to evolve siloed sales force strategies to 360° customer service models?
  • What are the keys to success when building and managing a pharmaceutical customer service portal? What types of features do physician expect from these sites?

Session 1: Tuesday, August 4, 11:00 - 11:30 AM EDT
Register here: https://www2.gotomeeting.com/register/550629875

Session 2: Tuesday, August 4, 3:00 - 3:30 PM EDT
Register here: https://www2.gotomeeting.com/register/766231642

The webinar is intended for qualified business accounts.

About ePharma Physician® v9.0
ePharma Physician® v9.0 was conducted via online survey methodology in Q2 2009 among 1,517 online practicing U.S. physicians.

Since 2002, the study has determined the leading online physician destinations based on the number of physician visitors as well as the content satisfaction of those who visit. In-depth analysis of top product and corporate pharmaceutical websites, health portals, online journal sites, specialty-specific sites, newsletters and society sites is available as part of the ePharma Physician® v9.0 advisory service. Additional topics include interactive detailing, tech-enabled sales reps, video conferencing, web 2.0 technologies, email use and interest, and pharmaceutical customer service portals, as well as market data for 300+ leading pharmaceutical product websites including Abilify, Actonel, Actos, Advair, Ambien CR, Amitiza, Androgel, Aricept, Asmanex, Astelin, Avandia, Avastin, Avelox, Avodart, Boniva, Botox, Byetta, Celebrex, Chantix, Cialis, Cipro, Concerta, Coreg CR, Crestor, Cymbalta, Daytrana, Depo-Provera, Detrol LA, Diovan, Effexor XR, Enbrel, Evista, Flomax, Flonase, Flovent HFA, Forteo, Fosamax/Fosamax Plus D, Gardasil, Geodon, Humira, Imitrex, Invega, Januvia, Lamictal, Latisse, Levaquin, Levitra, Lexapro, Lipitor, Loestrin 24 Fe, Lovaza, Lovenox, Lunesta, Lupron, Lyrica, Mirena, Namenda, Nasacort, Nasonex, Nexium (purplepill.com), NuvaRing, Pegasys, Plavix, Prevacid, Pristiq, ProAir HFA, Protonix, Provigil, Pulmicort, Relpax, Remicade, Requip, Risperdal, Rozerem, Seasonale, Seasonique, Seroquel, Singulair, Spiriva, Strattera, Symbicort, Tamiflu, Tekturna, Topamax/Topamax360, TriLipix, Ultram ER, Valtrex, Veramyst, Vesicare, Viagra, Vytorin, Vyvanse, Wellbutrin XL, Xyzal, Yaz, Zetia, Zithromax, Zoloft, Zyprexa, Zyvox. A complete list of available product sites is available at http://www.manhattanresearch.com/files/PRESS/ePharma_Physician_v9.0_Product_Site_Listing.pdf.

ePharma Physician® v9.0 also includes the following specialist segments in the research: Allergy and Immunology, Cardiology (Cardiovascular Surgery and Interventional Cardiology), Dermatology, Emergency Medicine, Endocrinology, Family Medicine/General Practice, Gastroenterology, Infectious Disease or HIV physician, Internal Medicine, Nephrology, Neurology, OB/GYN, Oncology-Hematology & Medical, Ophthalmology, Pediatrics, Psychiatry, Pulmonology, Radiology, Rheumatology, Surgery (General), and Urology.

For additional product and subscription information, please visit www.manhattanresearch.com/products/Strategic_Advisory/ePP.

About Manhattan Research
Manhattan Research, a Decision Resources, Inc. company, is a leading market research and advisory services firm for global pharmaceutical and healthcare companies. For more information, visit www.manhattanresearch.com.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.decisionresourcesinc.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...